长期护理机构居民使用奈玛特韦/利托那韦的潜在药物相互作用
该队列研究利用长期护理数据合作组织电子给药记录链接医保索赔数据,评估2022年1月至2025年1月美国长期护理机构居民使用奈玛特韦/利托那韦时与236种潜在相互作用药物的同日暴露情况。在48,260名居民中,86%至少暴露于1种潜在药物相互作用,最常见为阿托伐他汀、氨氯地平和阿哌沙班,重叠暴露中位天数为5至6天;禁忌性相互作用不常见,但需持续药物审查和药师监督。
要点
- 长期护理机构居民使用奈玛特韦/利托那韦时,86%存在至少1种潜在药物相互作用。
- 最常见潜在相互作用药物为阿托伐他汀(28.1%)、氨氯地平(21.6%)和阿哌沙班(15.9%)。
- 潜在相互作用多需临时停药或调整剂量而非禁忌,重叠暴露中位5至6天。
核心结论
- 长期护理机构居民使用奈玛特韦/利托那韦时潜在药物相互作用常见,但禁忌性相互作用不常见。
- 研究结果强调需要持续药物审查以及临床医生和药师监督以确保长期护理机构中抗病毒药物的安全使用。
研究设计与样本
- 研究为队列研究,使用长期护理数据合作组织的电子给药记录数据并链接Medicare索赔数据(2022年1月至2025年1月)。
- 共纳入48,260名接受奈玛特韦/利托那韦治疗的长期护理机构居民,平均年龄78.8岁(SD 10.9),58%为女性,76%为非西班牙裔白人。
- 评估了236种潜在相互作用药物的同期暴露,潜在药物相互作用定义为同日共同给药。
主要发现
- 86%的居民至少暴露于1种潜在药物相互作用。
- 最常见的潜在相互作用药物为阿托伐他汀(28.1%;95% CLs 27.7-28.50)、氨氯地平(21.6%;95% CLs 21.2-21.9)和阿哌沙班(15.9%;95% CLs 15.6-16.3)。
- 重叠暴露的中位天数为5至6天。
- 潜在药物相互作用最常涉及需要临时停药或调整剂量的药物,而非禁忌药物。
关键数值与推荐
- 潜在药物相互作用定义为同日共同给药,反映同期暴露而非临床不良效应。
- 共评估236种潜在相互作用药物。
临床怎么用
- 长期护理机构居民使用奈玛特韦/利托那韦前应进行药物审查,重点关注他汀类、钙通道阻滞剂和抗凝药等常见潜在相互作用药物。
- 对于需临时停药或调整剂量的药物,应制定相应管理计划,并加强临床医生和药师监督。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral for COVID-19. Although effective, its use is complicated by clinically important potential drug-drug interactions (DDIs). Long-term care facility (LTCF) residents are especially vulnerable to both COVID-19 and the adverse effects of potential DDIs because of advanced age, multimorbidity, and polypharmacy. The objective of this study was to quantify the prevalence and duration of potential DDIs among US LTCF residents administered nirmatrelvir/ritonavir. DESIGN: We conducted a cohort study of LTCF residents using electronic medication administration record data from the Long-Term Care Data Cooperative linked to Medicare claims (January 2022-January 2025). METHODS: Days of nirmatrelvir/ritonavir administration were identified, and concurrent exposure to 236 potentially interacting medications was assessed. A potential DDI was defined as same-day coadministration, reflecting concurrent exposure rather than clinical adverse effects. We estimated the prevalence of potential DDIs and the median duration of overlapping exposure. RESULTS: Among 48,260 LTCF residents treated with nirmatrelvir/ritonavir, the mean age was 78.8 years (SD, 10.9), 58% were female, and 76% were non-Hispanic White. Overall, 86% were exposed to at least 1 potential DDI. The most common potentially interacting medications were atorvastatin (28.1%; 95% confidence limits [CLs], 27.7-28.50), amlodipine (21.6%; 95% CLs, 21.2-21.9), and apixaban (15.9%; 95% CLs, 15.6-16.3). Median days of overlapping exposure ranged from 5 to 6 days. DISCUSSION: Potential DDIs most frequently involve medications requiring temporary withholding or dose adjustment rather than contraindication. The high prevalence of potential DDIs likely reflects the complexity of medication management in LTCFs, where antiviral use must be weighed against comorbidities and polypharmacy. CONCLUSIONS AND IMPLICATIONS: Potential DDIs with nirmatrelvir/ritonavir were common among LTCF residents, though contraindicated ones were uncommon. These findings underscore the need for ongoing medication reviews and clinician and pharmacist oversight to ensure safe antiviral use in LTCFs.
引用
- Khan MA, Daiello LA, Berry SD, et al. Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents. J Am Med Dir Assoc. 2026. PMID: 42413156. doi:10.1016/j.jamda.2026.106365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。